Vijay Mahant is the President and CEO of Renova Therapeutics, working in gene therapy for Congestive Heart Failure, NASH, and Type-2 Diabetes. Prior to this role, Mahant served as the Founder and CEO of MediLite Diagnostika, focusing on ultra-sensitive technology for molecular and immuno-diagnostics. Vijay holds a MS and PhD from Loughborough University.
September 1, 2021 - present